Loading
Life sciences · Journal article
Discover Oncology · September 20, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Comprehensive genomic profiling (CGP) has been increasingly implemented in clinical practice; however, only a limited proportion of patients ultimately receive genomically matched therapies. The BRAF V600E mutation is extremely rare in gastric cancer, and effective targeted treatment strategies remain undefined. A 63-year-old woman developed a tumor in the right ureter 3 years after gastrectomy for gastric cancer and was diagnosed with recurrent disease. She was initially treated with S-1 plus oxaliplatin and nivolumab; however, the disease progressed. CGP revealed a BRAF V600E mutation, and she subsequently received combination therapy with dabrafenib and trametinib under the Japanese health insurance system. The treatment resulted in a partial response, with a progression-free survival of approximately 6 months and manageable toxicity. To our knowledge, this is the first reported case of BRAF V600E–mutated gastric cancer treated with combined BRAF and MEK inhibition. This case highlights the potential clinical efficacy of dabrafenib plus trametinib, as well as the value of CGP in identifying actionable alterations in gastric cancer.